menu
    • menu
    [{"orgOrder":0,"company":"Inflazome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Inzomelid","moa":"NLRP3","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inflazome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inflazome \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inflazome \/ Inapplicable"},{"orgOrder":0,"company":"Inflazome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Inzomelid","moa":"NLRP3","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inflazome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inflazome \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inflazome \/ Inapplicable"},{"orgOrder":0,"company":"Inflazome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Somalix","moa":"NLRP3","graph1":"Immunology","graph2":"Phase I","graph3":"Inflazome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inflazome \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inflazome \/ Inapplicable"},{"orgOrder":0,"company":"Inflazome","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Inzomelid","moa":"NLRP3","graph1":"Neurology","graph2":"Phase I","graph3":"Inflazome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inflazome \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Inflazome \/ F. Hoffmann-La Roche"}]

    Find Clinical Drug Pipeline Developments & Deals by Inflazome

    Menu

    Inflazome

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Inflazome

                            Ireland arrow
                            American Thoracic Society
                            Not Confirmed

                            Inflazome

                            Ireland arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inzomelid

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Inflazome Announces its Acquisition by Roche

                            Details : The acquisition gives Roche full rights to Inflazome’s entire portfolio which is composed of clinical and preclinical orally available small molecule NLRP3 inhibitors.

                            Product Name : IZD174

                            Product Type : Other Small Molecule

                            Upfront Cash : $441.9 million

                            September 21, 2020

                            Lead Product(s) : Inzomelid

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Inflazome

                            Ireland arrow
                            American Thoracic Society
                            Not Confirmed

                            Inflazome

                            Ireland arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inzomelid

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Grants Orphan Drug Designation for Inflazome’s Inzomelid for the Treatment of Cryopyrin-Associated Perio...

                            Details : Inzomelid is a potent, selective, orally-available, brain-penetrant NLRP3 inflammasome inhibitor intended for treatment of debilitating inflammatory diseases.

                            Product Name : IZD174

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 14, 2020

                            Lead Product(s) : Inzomelid

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Inflazome

                            Ireland arrow
                            American Thoracic Society
                            Not Confirmed

                            Inflazome

                            Ireland arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inzomelid

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Inzomelid completes Phase I studies and shows positive results in the treatment of Cryopyrin-Associated Period...

                            Details : The Phase I study demonstrated Inzomelid has an excellent safety, tolerability and pharmacokinetic profile in healthy subjects, with dose-dependent target engagement.

                            Product Name : IZD174

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 26, 2020

                            Lead Product(s) : Inzomelid

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Inflazome

                            Ireland arrow
                            American Thoracic Society
                            Not Confirmed

                            Inflazome

                            Ireland arrow
                            American Thoracic Society
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Somalix

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Inflazome’s Somalix Demonstrates Positive Safety, Tolerability and Pharmacodynamic Profile in its Phase I St...

                            Details : Results from the first-in-human study showed excellent safety, tolerability and pharmacokinetics in healthy subjects resulting in target engagment at all doses tested.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 27, 2020

                            Lead Product(s) : Somalix

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth